WJB 001
Alternative Names: WJB-001Latest Information Update: 12 Sep 2025
At a glance
- Originator Wigen Biomedicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Exportin 1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 10 Jul 2025 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in China (PO) (NCT06953323)
- 01 May 2025 Wigen Biomedicine Technology plans a phase I/II trial for Solid tumours (Late-stage disease, Combination-therapy, Second-line therapy or greater) in China (PO, Capsule), in May 2025 (NCT06953323)
- 05 May 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05773820)